Abstract The fungal pathogen Candida albicans transforms arachidonic acid (AA) into 3-hydroxyarachidonic acid [3(R)-HETE], and we investigated if its nonpathogenic and 3(R)-HETE-producing close relative, Dipodascopsis uninucleata, could similarly transform the endocannabinoid/endovanilloid anandamide into 3-hydroxyanandamide (3-HAEA). We found that D. uninucleata converts anandamide into 3-HAEA, and we therefore developed an enantiodivergent synthesis for this compound to study its pharmacological activity. Both enantiomers of 3-HAEA were as active as anandamide at ele- 
Fungi belonging to the Candida species (Ascomycetes; class Saccharomycetes) are among the most abundant fungal pathogens and cause of infections (candidiasis) in humans. They colonize a wide range of micro environments in the human body, and not only cause damage of the skin, nails, oral, or vaginal epithelium, but are also frequently involved in life-threatening infections. Candida species are opportunistic pathogens and cause nosocomial infections (disseminated candidiasis) that are particularly severe in cancer patients under chemotherapy or in immunocompromised individuals (1) (2) (3) (4) (5) (6) . They also cause mucocutaneous infections, such as vulvovaginal candidiasis, the most prevalent superficial fungal infection in women with acquired immunodeficiency syndrome (AIDS) and diabetes mellitus, or assuming oral contraceptives, antibiotics, and corticosteroids. The symptoms of vaginal candidiasis include itching, burning, soreness, abnormal vaginal discharge, dysparunia, as well as vaginal and vulvar erythema (7) . C. albicans is the most prevalent pathogenic fungal species, and accounts for approximately 75% of all infections in women during the child-bearing period (8) . Although C. albicans exists in the vagina of most of the women as an innocuous commensal organism with no apparent symptoms or clinical signs (9) , it can also cause untreatable problems. Thus, due to its incomplete clearance by therapy with antimycotics, several women diagnosed with an episode of sporadic vulvovaginal infection experience subsequent recurrent episodes of acute vulvovaginitis.
When looking at the major symptoms of candidiasis, particularly vulvar itching, burning, soreness, and erythema, it is possible to hypothesize that at least some of them are: 1) mediated by activation of transient receptor potential of vanilloid type-1 (TRPV1) channels (10, 11) ; and 2) accompanied by the formation of endogenous ligands (endocannabinoids) of cannabinoid receptors of type 1 and 2 (CB 1 and CB 2 ), the activation of which is known to counteract itch, pain, and inflammation (12, 13) . In fact, it has been shown that vulvodynia, a condition characterized by painful burning sensation, allodynia, and hyperalgesia in the region of the vulval vestibules, is accompanied by increased expression of TRPV1 receptors (14) . On the other hand, inflammatory conditions causing pain are known to be counteracted by compounds that elevate the tissue levels of anandamide by inhibiting its cellular uptake or, alternatively, by interfering with its enzymatic hydrolysis (15, 16) . Remarkably, there is also growing awareness that anandamide can activate TRPV1 receptors, especially during various inflammatory and pronociceptive conditions, and when its activity at CB 1 receptors is blocked and the sensitivity of TRPV1 receptors is enhanced by its phosphorylation or overexpression (17, 18) .
The oxylipin 3(R)-hydroxy-5,8,11,14-eicosatetraenoic acid [3(R)-HETE] (Fig. 1) , an intermediate of the b-oxidation of arachidonic acid (AA), has an important biological role in the life cycle of fungi, and was first described in the nonpathogenic species Diposascopsis uninucleata (19) , where its formation is associated with morphogenesis during the sexual life cycle. During infection by C. albicans, host cells produce AA to counteract this process, but Candida is able to utilize AA released from host cells to form 3(R)-HETE and related compounds through a well-characterized process utilizing its fatty acid b-oxidation pathway (20) . 3 (R)-HETE is associated with hyphal forms of Candida and is important for their anchorage to host cells during infection (21) . Thus, Candida can chemically modify the metabolites of the host cell to facilitate infection. Notwithstanding the presence of a C-3 hydroxyl, 3(R)-HETE is a substrate of cyclooxygenase-2 (an enzyme up-regulated during candidiasis), thereby generating compounds that, like 3(R)-hydroxy-PGE 2 , are capable to induce interleukin-6 gene expression via the EP 3 receptor (22, 23) , and to ultimately trigger further inflammation cascades.
In view of the chemical similarity between anandamide and AA, and their capability to be both recognized by several oxygenating enzymes (see for review Ref. 24) , we have hypothesized that a 3(R)-HETE-producing fungus would be capable to convert anandamide into its 3-hydroxy-derivative, thus potentially altering its cannabinoid and vanilloid profile at the site of infection. To investigate this issue and evaluate its clinical implications, we have studied the metabolism of anandamide by D. uninucleata (19) and have developed an enantiodivergent synthesis of 3-hydroxy-anandamide (3-HAEA) (Fig. 1) , a so-far unknown oxylipin, to explore its biological activity.
MATERIALS AND METHODS
Fungal culture and incubation with AA D. uninucleata (Lipomycetaceae, Saccharomycetales, Saccharomycetidae, Saccharomycetes, Ascomycota, UOFS-Y128, South African Strain obtained from Prof. Kock., The University of the Orange Free State, Bloemfontein, South Africa) was grown in yeast nitrogen base medium up to the initial phase of the sexual cycle. Two aliquots of 50 ml of culture were incubated with 100 mM anandamide. Fifty ml of culture were incubated with 100 mM AA as a positive control. A fourth 50 ml aliquot was incubated with vehicle (10 ml methanol) as a negative control. After 6 h of incubation at 37°C the first 50 ml batch of anandamide incubate and the batches incubated with AA and vehicle were spun down at 300 g. The pellet (2.5 ml) was suspended in 4 ml of phosphate buffered saline and subjected to mechanical breaking under liquid N 2 . After 12 h of incubation, the second batch of anandamide incubate was subjected to mechanical breaking. Broken cells were subjected to lipid extraction with 4 ml of methanol and 8 ml of chloroform. After separation of the organic phase, the residual phase was extracted two more times with 8 ml of chloroform. Chloroform phases were pooled and dried under vacuo. The extract was dissolved in 1 ml of methanol. One hundred microliters of this solution were analyzed by HPLC carried out on a reverse phase column (25 cm (R,S) -Benzhydryl but-2-enoate epoxide (4a,b). To a cooled (ice bath) solution of benzhydryl but-2-enoate (2.0 g, 7.9 mmol) in dichloromethane (100 ml), solid NaHCO 3 (333 mg, 3.95 mmol, 0.5 equiv.) was added, and to this suspension a solution of 85% meta-chloroperoxybenzoic acid (MCPBA, 1.31 g, 9.5 mmol, 1.2 equiv.) in dichloromethane (50 ml) was added dropwise over 15 min. After stirring 1 h at 0°C and 10 h at room temperature, the reaction was worked up by filtration over neutral alumina to remove meta-chlorobenzoic acid and unreacted MCPBA, and the filtration cake was washed with CH 2 Cl 2 . The pooled filtrates were evaporated, and the residue was purified by GCC on silica gel (75 g, petroleum ether-EtOAc 8:2 as eluant), affording 1.47 g (69%) 4a,b as a colorless oil. 1 (S) -Benzhydryl but-2-enoate epoxide (4a). To a stirred solution of 4a,b (2.0 g, 7.45 mmol) in THF (0.2 ml), (S,S)-salen-Co. (10 mg, activated by reaction with acetic acid in toluene) was added. After complete solubilization, water (72 ml) was added, and stirring was continued at room temperature by monitoring the course of the reaction by HPLC (methanol-water gradient, from 5:5 to 9:1 in 20 min). After 120 h, the reaction was worked up by the addition of 2N H 2 SO 4 and extraction with EtOAc. After washing with brine and drying, the organic phase was evaporated, and the residue was purified by GCC on silica gel (25 g, petroleum ether/ ether 8:2 as eluant) to afford 700 mg (35%) of 4a as a colorless oil. The optical purity, checked after conversion to 5a and HPLC analysis of its diastereomeric Mosher esters, was .95%. Conditions of analysis: Simmetry C-18 column, methanol/water 7:3 as eluant, Rt of R-ester: 11.60 min; Rt of S-ester: 14.00 min.
(R)-Benzhydryl 3-hydroxyhex-5-ynoate (5a). To a cooled (225°C) solution of trimethylsilyl acetylene (2.2 ml, 1.5 g, 14.9 mmol, 2 equiv.) in dry toluene (15 ml), butyl lithium (2.5 M in hexanes, 6.0 ml, 14.9 mmol. 2 equiv) was added dropwise. The resulting milky suspension was stirred at 215°C for 15 min, and then warmed to 0°C by replacement of the dry ice/acetone with a ice/water cooling bath. Transmetalation was carried out by the dropwise addition of diethylaluminum chloride (1.0 M in hexanes, 15.0 ml, 149 mmol, 2 mol. equiv.) and stirring at 0°C for 1 h, and then a solution of the (S)-epoxide 4a (2.0 g, 7.45 mmol) in toluene (10 ml) was added dropwise. After stirring for 2 h at room temperature, the solution was worked up by neutralization with sat. NH 4 Cl, acidification with 1 M HCl, and extraction with EtOAc. The organic phase was dried and evaporated, and the residue was dissolved in THF (10 ml) and then treated at 0°C with 1.0 M TBAF (7.45 ml, 7.45 mmol) in THF. After stirring 30 min at 0°C, the reaction was worked up by the addition of brine, and extracted with ether. The organic phase was dried (Na 2 SO 4 ) and evaporated, and the residue was purified by GCC on silica gel (25 g) with petroleum ether-ether 7:3 as eluant, affording 1.3 g (61%) 5a as a colorless oil. 1 Benzhydryl 3-hydroxyicosa-5,8,11,14-tetraynoate (7a). To a solution of 5a (1.0 g, 3.4 mmol, 1 equiv) and 1-bromotetradeca-2,5,8-triyne (6, 906 mg, 3.4 mmol, 1 equiv) in DMF (5ml), a well-amalgamated (mortar) mixture of CuI (1.3 g, 6.8 mmol, 2 equiv), NaI (1.0 g, 6.8 mmol, 2 equiv), and K 2 CO 3 (705 mg, 5.1 mmol, 1.5 equiv) was added. The suspension was stirred at room temperature under nitrogen atmosphere for 10 h, and then worked up by the addition of 30% ammonia and ether. The organic phase was washed with brine, dried, and evaporated, and the residue was purified by GCC on silica gel (25 g, petroleum ether-ether 4/6 as eluant) to afford 1.1 g (78%) 7a as an orange oil. 1 2 (831 mg, 4.7 mmol) in absolute ethanol (10 ml), NaBH 4 (178 mg, 4.7 mmol) was added. After stirring at room temperature for 10 min, ethylendiamine (334 mg, 4.7 mmol) was added dropwise, and hydrogen was then bubbled through the suspension for 10 min. A solution of 7a (1.0 g, 2.1 mmol) in abs. ethanol (5 ml) was next added dropwise, and the reaction was stirred at room temperature, monitoring its course by TLC on silver-coated plates (petroleum ether-ether 4:6; Rf starting material: 0.50; Rf reaction product: 0.70). After 250 min, the reaction was worked up by filtration over Celite, dilution with water, and extraction with ether. The organic phase was washed with 2N H 2 SO 4 , dried (Na 2 SO 4 ), and evaporated, and the residue was dissolved in CH 2 Cl 2 (6.5 ml) and treated with trifluoroacetic acid (TFA, 100 ml). After stirring at room temperature for 10 min, the reaction was worked up by dilution with brine and extraction with CH 2 Cl 2 . The organic phase was washed with brine, dried, and evaporated, and the residue was purified by GCC on silica gel (12.5 g, petroleum ether/ether 3:7 as eluant) to afford 342 mg (51% from 7a) 1a as a yellowish oi1, whose 1 H NMR and 13 C NMR data were identical to those reported in the literature (29) .
To a solution of 1a (50 mg, 0.14 mmol) in CH 2 Cl 2 (1ml), triethylamine (78 ml) and PPAA (50% in EtOAc, 102 ml) were added. After stirring 30 min at room temperature, ethanolamine (78 ml, 57 mg, 0.56 mmol, 4 equivalents) was added, and reaction was stirred at room temperature for 2 h, and then worked up by the addition of 2N H 2 SO 4 and dilution with CH 2 Cl 2 . The organic phase was washed with brine, dried, and evaporated, and the residue was purified by GCC on silica gel (2.5 g, petroleum ether/EtOAc 7:3 as eluant), to afford 23 mg (43%) 2a as a pale-yellow oil. 
Mass spectrometric analysis of synthetic and natural 3-HAEA
Liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry (LC-APCI-MS) was performed by using a Shimadzu high-performance liquid chromatography (HPLC) apparatus (LC-10ADVP) coupled to a Shimadzu quadrupole mass spectrometer (LCMS-2010) via a Shimadzu APCI interface. The temperature of the APCI source was 400°C; the HPLC column was a Phenomenex (5 mm, 150 3 4.5 mm) reverse phase column, eluted by using methanol/water/acetic acid 85/15/0.01 as the mobile phase with a flow rate of 1 ml/min. High resolution LC-MS/MS analysis was carried out with liquid chromatographyelectrospray-ion trap-time of flight (LC-ESI-IT-ToF) by using an IT-ToF mass spectrometer (Shimadzu) in conjunction with an LC-20AB (Shimadzu). LC separation was performed using a Discovery: C18 column (15cm 3 2.1mm, 5 mm) and methanol/ water/acetic acid 85/15/0.01 as the mobile phase with a flow rate
TRPV1 receptor assays
HEK-293 cells stably overexpressing recombinant the human TRPV1 cDNA (17) were grown as monolayers in minimum essential medium supplemented with nonessential amino acids, 10% fetal calf serum, and 2 mM glutamine, and maintained under O 2 / CO 2 (95%/5%) at 37°C. The effect of test substances on intracellular Ca 21 concentration was determined by using Fluo-4, a selective intracellular fluorescent probe for Ca 21 . On the day of the experiment, the cells were loaded 21 ] i . All determinations were at least performed in triplicate. Curve fitting and parameter estimation was performed with GraphPad Prism: (GraphPad Software Inc., San Diego, CA). Statistical analysis of the data was performed by ANOVA at each point using ANOVA followed by Bonferroniʼs test. Differences were considered significant at the P , 0.05.
Binding assays at CB 1 
Patch clamp electrophysiology
HEK 293 cells stably expressing TRPV1 were recorded in a continuously perfused recording chamber (500 ml volume) mounted on the stage of an inverted microscope. The standard bath solution consisted of (in mM): 140 NaCl, 5 CsCl, 2 MgCl 2 , 10 HEPES, 10 D-glucose pH 7.4 (NaOH). The pipette solution contained (in mM) 140 CsCl, 4 MgCl 2 , 5 EGTA, 10 HEPES, pH 7.2 (CsOH). All experiments were performed at room temperature using a HEKA EPC-9 amplifier (HEKA Electronics, Germany). Patch pipettes of 3-5 MV were fabricated from borosilicate glass capillaries. Experiments were carried out and analyzed under the control of the Pulse and Pulsefit software (HEKA Electronics, Germany). Series resistances were ,10 MV, and were compensated by 75-85%. Stated membrane potentials always refer to the physiological inner side of the membrane. 
RESULTS

Enantiodivergent synthesis of 3-hydroxy-eicosatetraenoic acid (3-HETE) and 3-HAEA enantiomers
Synthetic 3(R)-HETE was obtained by semisynthesis from 5,6-epoxyarachidonic acid (25) , or, alternatively, by total synthesis from (R)-epichlorohydrin (26); we developed an alternative and more versatile asymmetric enantioselective synthesis of enantiomers 3(R)-HAEA (2a) and 3(S)-HAEA (2b) from benzhydryl-but-2-enoate oxide (3) (Fig. 2) . Jacobsen hydrolytic kinetic resolution was used to establish the C-3 stereocenter and prepare multigram amounts of the enantiopure (.95% ee) epoxides 4a and 4b, next regioselectively opened with the acetylenic alane derived from trimethylsilylacetylene (27) to give, after desilylation, the C-6 propargylic alcohols 5a and 5b. Coupling with the tri- acetylenic C-14 propargylic bromide 6 (28) under copper (I) promotion, afforded the C-20 tetrayne esters 7a and 7b. Semireduction with Nickel boride to the corresponding tetraenic esters, and deprotection with trifluoroacetic acid led to the enantiomeric HETEs 1a and 1b, eventually coupled with ethanolamine under PPAA (propylphosphonic acid anhydride) (29) promotion to afford 3(R)-HAEA and 3(S)-HAEA (2a and 2b, respectively). After amidation with ethanolamine, both homochiral 3-HAEA enantiomers (.95% ee) were used for biological profiling.
Identification of 3-HAEA in D. uninucleata incubates
Lipid extracts from incubates of the D. uninucleata with anandamide or vehicle were purified by semipreparative reverse-phase HPLC (Fig. 3A) . The HPLC fractions at 13-16 min contained a component more hydrophilic than anandamide (retention time 20 min, see later discussion), which was produced in an yield of approximately 5% with respect to the peak of anandamide. This HPLC component was the only peak that was virtually absent from the HPLC chromatogram relative to the incubate carried out in the absence of anandamide (Fig. 3A, red line) . Under the same incubation conditions approximately 10% of AA was transformed into 3-HETE (data not shown). Preliminary identification of this peak was performed by LC-APCI-MS analysis. This allowed the identification of the LC peak at retention time 8 min. The mass spectrum exhibits the ions at m/z 5 346, as the base peak, and 328, due to the loss of one or two water molecules from the molecular ion peak, respectively (Fig. 3B) . The identity of 3-HAEA was established through use of reverse-phase HPLC coupled to electrospray IT-ToF mass spectrometry, which accomplishes high accuracy mass measurement. The mass spectrum, in positive mode, of the HPLC fraction 13-16 of (Fig. 3C) . The retention time on HPLC and the measured masses for each peak coincided with the theoretical ones calculated from the corresponding chemical formula within # 8 ppm (data not shown). The peak at m/z 5 368.2537 was subjected to further analysis by MS 2 , which yielded a major fragment at m/z 5 350.2410 (data not shown), corresponding to the chemical formula of C 22 H 33 NO 1 Na, and interpreted as the parent ion with loss of one further molecule of water ([M 1 Na -2H 2 0] 1 ). The major peak in the chromatogram shown in Fig. 3A (retention time 20 min) was identified as anandamide, which also yields as the only peak the molecular ion plus Na 1 (C 22 H 37 NO 2 1 Na, m/z 5 370.2750, within 8.9 ppm of the expected mass). In agreement with the identity of the unknown component as 3-HAEA, synthetic 3(R)-HAEA was analyzed by LC-IT-ToF under the same conditions and yielded a peak at exactly the same retention time and with a superimposable MS fragmentation pattern, with m/z values almost identical (within 2 ppm) to those of the compound isolated from D. uninucleata extracts (Fig. 3D) . It must be pointed out, however, that the observed mass spectrum is also compatible with the molecular formula and fragmentation pattern of the potential biosynthetic precursor of 3-HAEA via the b-oxidation pathway (i.e., the 2,3-D-AEA, of which, unfortunately, we do not possess an authentic standard). At any rate, when the synthetic compound was coanalyzed with the extract, only one homogeneous peak with this fragmentation pattern was observed (data not shown).
Activity of 3(R)-HAEA and 3(S)-HAEA at human recombinant TRPV1 receptors
Using a fluorometric test, we showed that human TRPV1-expressing HEK293 cells exhibit a sharp increase in intracellular Ca 21 upon application of 3(R)-HAEA and 3(S)-HAEA. The activity of the compounds was normalized to the maximum intracellular Ca 21 elevation generated by application of 4 mM ionomycin. Using this test, we determined the concentration for half-maximal activation to be 0.45 6 0.02 mM (hill slope 0.92 6 0.02) and 0.39 6 0.02 mM (hill slope 1.02 6 0.02), respectively ( Fig. 4 and Table 1 ). The maximal effect at 10 mM was 78.3 6 0.6% and 79.4 6 0.7% of the effect of ionomycin 4 mM. Iodoresiniferatoxin (0.1 mM), a known blocker of TRPV1, inhibited the effect at 10 mM of both (96.8 6 3.2% and 96.6 6 3.7% inhibition, respectively). 3(R)-HETE and 3(S)-HETE were significantly less active (Fig. 4) .
Activity of 3(R)-HAEA on TRPV1-mediated currents
We performed whole-cell voltage clamp recordings to test whether TRPV1 currents can directly be activated by 3(R)-HAEA. HEK-293 cells heterologously expressing human TRPV1 responded with large inward and outward current to the application of 20 mM 3(R)-HAEA (Fig. 5A) . The current voltage curves obtained resemble the basic characteristics of TRPV1. Moreover, the elicited current could be blocked by the TRPV1 antagonist capsazepine Both enantiomers of 3-HAEA exhibited similar affinity for both human CB 1 and CB 2 receptors, and significantly (?70-90-fold and ?40-60-fold) lower affinity than the parent compound anandamide, as shown in Table 1 .
DISCUSSION
The first aim of this study was to investigate whether or not anandamide, an endocannabinoid and endovanilloid mediator, can be transformed by the Candida cognate fungus D. uninucleata into its 3-hydroxy derivative. Additionally, in order to assist with the identification of putative 3-HAEA from the conversion experiments and eventually obtain it in amounts sufficient to profile its activity at cannabinoid and TRPV1 receptors, we have synthesized here for the first time 3(R)-and 3(S)-HAEA. We have shown that these synthetic compounds are chromatographically and massspectrometrically indistinguishable from a metabolite obtained after incubation of D. uninucleata with anandamide, and that, compared with the latter compound, they exhibit dramatically reduced binding activity at both cannabinoid receptors types, while retaining activity at TRPV1 receptors, as shown by their capability to increase intracellular Ca 21 and to induce cation-mediated currents in HEK-293 cells overexpressing human recombinant TRPV1 channels.
Anandamide affinity and functional potency at TRPV1 receptors are about one order of magnitude lower than those at CB 1 receptors (30) (31) (32) . Therefore, endogenous anandamide can be predicted to act predominantly as an endocannabinoid and, by activating CB 1 and CB 2 receptors, to inhibit the pronociceptive and proinflammatory actions of TRPV1 agonists (33, 34) . However, anandamide was shown to activate TRPV1 receptors when CB 1 receptors are blocked and/or when TRPV1 channels are sensitized by stimuli, like those occurring during inflammatory reactions (17, 18, (35) (36) (37) (38) (39) . TRPV1 sensitization likely occurs during candidiasis, because increased expression of vulvar TRPV1 receptors is observed during vulvodynia, a condition similar to that caused by candidiasis (14) , and clotrimazole, a widely used antimycotic agent, was suggested to owe its inflamma- tory and algogenic side effects to its capability to activate TRPV1 receptors (40) . On the other hand, several peripheral inflammatory conditions causing pain and/or itch are known to be accompanied by elevated levels of anandamide as an adaptive reaction to counteract these symptoms, as suggested by the observation that compounds that prolong the life span of anandamide by inhibiting its inactivation exert anti-inflammatory effects (15, 16, (41) (42) (43) (44) (45) (46) (47) . Thus, it seems reasonable to hypothesize that, during candidiasisinduced inflammation, on the one hand TRPV1 is sensitized, and, on the other hand, anandamide is produced by host or neighboring cells. Thus, Candida species might partly transform endogenously produced anandamide into 3-HAEA, as observed here for D. uninucleata, thus leading to the formation of a predominantly antihyperalgesic and anti-inflammatory mediator into a "pure" TRPV1 agonist. This mechanism might contribute to some of the typical symptoms of candidiasis.
Clearly, further experiments that are beyond the aims of the present study are needed in order to corroborate or rule out this hypothesis. First, it will be necessary to assess if the conversion of anandamide into 3-HAEA does occur also during candidiasis, and, if so, to what extent. The production of 3-hydroxyeicosanoids like 3-hydroxyPGE 2 upon infection of HeLa cells with C. albicans supports the hypothesis that also 3-HAEA might be formed during infection with this pathogenic fungus (23) . On the other hand, still enough endogenous anandamide to activate CB 1 and CB 2 receptors might remain even if this conversion were to occur in vivo, and this would counteract the effects of 3-HAEA. A second issue for future studies should be the assessment of the relative regulation of TRPV1 and cannabinoid receptors during candidiasis. Furthermore, the activity of 3-HAEA should also be investigated in "native" cells that constitutively express TRPV1 receptors, since a higher potency has been reported, at least for anandamide, at activating these channels when they are overexpressed in cells (30) (31) (32) . Finally, the configuration of 3-HAEA produced from D. uninucleata needs to be investigated to clarify if this compound is produced through the same pathway (boxidation) as 3(R)-HETE, as it might seem unlikely given the fact that anandamide is not capable of making the ester with CoA, which is necessary for entering this catabolic route. The alternative possibility that 3-HAEA is produced by cytochrome p450/oxigenase-catalyzed 3-hydroxylation of anandamide would be, instead, suggested by the fact that this latter compound is recognized as substrate by several enzymes of the AA cascade (24) . At any rate, we have shown here that the configuration of 3-HAEA has little biological relevance in terms of activation of either TRPV1 or cannabinoid receptors. It would be also important to assess if the other major endocannabinoid, 2-arachidonoylglycerol, which has little activity at TRPV1 receptors (30) (31) (32) , and is more abundant than anandamide in tissues, is converted by 3-(R)-HETE-producing fungi.
In conclusion, we have provided evidence that a 3-HETEproducing fungus can act in vitro upon the anandamide potentially released by host or neighboring cells during candidiasis, thus catalyzing its transformation into a compound that is no longer capable to activate cannabinoid receptors but retains agonist activity at the TRPV1 channel. Our study might suggest that compounds capable to prolong the lifespan of anandamide by inhibiting its inactivation, and that have proved useful in several animal models of pain, inflammation, and itch (15, 16, (41) (42) (43) (44) (45) (46) (47) (48) , might not be necessarily suitable for the symptomatic treatment of candidiasis, as they might also promote the formation of 3-HAEA, a likely algogenic compound. Furthermore, our data provide an unusual example of the typical capability of pathogenic microorganisms to control, or even exploit, innate defense mechanisms to facilitate infection (49, 50) .
